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Previous studies have reported that KIOM-79 shows a strong inhibitory eﬀect on AGE formation and inhibited a proinﬂammatory
state in a murine macrophage cell line. In the present study, we investigated the eﬀect of KIOM-79 on AGE accumulation and
vascular inﬂammation in the aorta of Zucker diabetic fatty (ZDF) rats, a commonly used model of type 2 diabetes. Seven-
week-old male ZDF rats were treated with KIOM-79 (50mg/kg) once a day orally for 13 weeks. We examined the dissected
aortas for AGE accumulation, expression of the receptor for AGEs (RAGE), and the expression of proinﬂammatory factors,
including monocyte chemoattractant protein-1 (MCP-1), vascular endothelial growth factor (VEGF), and vascular adhesion
molecule-1 (VCAM-1). Nuclear factor-kappaB (NF-κB) and inducible nitric oxide synthase (iNOS) were also measured by
Southwestern histochemistry, electrophoretic mobility shift assay (EMSA), and immunohistochemistry, respectively. KIOM-79
markedly reduced the accumulation of AGEs and the expression of RAGE in the aorta. We also found that KIOM-79 attenuated
the expression of inﬂammatory factors including NF-κB, MCP-1, VEGF, VCAM-1, and iNOS in the aortas of ZDF rats. These data
suggest that KIOM-79 may prevent or retard the development of inﬂammation in diabetic vascular disease.
1.Introduction
Cardiovasculardiseaseisoneofthemostcommoncomplica-
t i o n so fd i a b e t e s[ 1]. Chronic hyperglycemia accelerates the
formation of advanced glycation end products (AGEs) and
accumulation of AGEs in various tissues. AGE accumulation
is an important feature in the development of diabetic
macrovascular complications, such as atherosclerosis and
cardiac dysfunction, and AGEs are believed to play a crucial
role in the pathogenesis of diabetic vascular inﬂammation
[2, 3]. AGE inhibitors, such as LR-90 and aminoguanidine
(AG), have anti-inﬂammatory properties and help protect
against diabetic vascular damage [4, 5]. The inhibition of
AGE formation, blockade of the AGE-RAGE interaction, and
suppressionofRAGEexpression or its downstream pathways
suggest novel therapeutic strategies for the treatment of the
vascular complications of diabetes [6, 7].
Traditional herbal medicines have been used for the
treatment of diabetes or diabetic complications in Korea and
Asian countries. The development of KIOM-79, which is a
mixture of the 80% ethanol extract of parched Puerariae
radix, gingered Magnoliae cortex, Glycyrrhizae rhizome, and
Euphorbiae radix, was based on the basic known function
of each herb used in traditional Korean medicine for a
variety of medical purposes, including diabetes and diabetic
complications [8–11]. In our previous studies, KIOM-79
has shown a stronger inhibitory eﬀect on AGE formation
than individual herbal medicines in vitro [12]. KIOM-79
has also reduced accumulation of AGEs in the kidney and
delayed the development of diabetic nephropathy in animal
m o d e l sf o rt y p e1a n d2d i a b e t e s[ 13–15]. Recent studies
have also helped to elucidate the mechanisms of KIOM-79’s
anti-inﬂammatory and cytoprotective properties. KIOM-
79 blocks both NF-κB and p38 kinase activation in a
murine macrophage cell [16] and induces hemoxygenase-
1 induction in a pancreas-beta cell line, increasing its
antioxidant capacity [17].
These pharmacological actions of KIOM-79 may be
useful for the vascular inﬂammation of the aorta in diabetes.
Therefore, the present study was designed to investigate the2 Evidence-Based Complementary and Alternative Medicine
eﬀects of KIOM-79 on the aortic inﬂammation in a rat
model of type 2 diabetes, the Zucker diabetic fatty (ZDF)
rat.
2. Methods
2.1. Preparation of KIOM-79. The cortex of Magnolia oﬃci-
nalis Rehd. et Wils. (Magnoliaceae), radix of Pueraria lobata
Ohwi (Leguminosae), radix of Glycyrrhiza uralensis Fisch
(Leguminosae), and radix of Euphorbia pekinensis Ruprecht
(Euphorbiaceae) were collected from the province Gamsuk
in China in 2003 identiﬁed by botanist Professor J. H. Kim
(DepartmentofLife Science,Kyungwon University, Republic
of Korea). All voucher specimens were deposited at the
herbarium of the Korea Institute of Oriental Medicine (nos.
1240, 2, 7, and 207, resp.). These medicinal herbs, which
constitute KIOM-79, were prepared as previously described
in [16]. The quality of KIOM-79 was controlled by HPLC
[14].
2.2. Animals and Treatments. All animal procedures were
carried out in accordance with the National Institute of
Health Guide for the Care and Use of Laboratory Animals
(NIH publication no. 85-23) and were approved by the
Committee on Animal Care of our institution. Male Zucker
diabetic fatty (ZDF fa/fa) rats and age-matched Zucker lean
(ZL fa/+ or +/+) rats were used (Charles River Laboratories,
USA) at six weeks of age. They were kept in an automatically
controlled room (the room temperature was about 24◦Ca n d
the humidity was about 60%) with a conventional lighting
regimen. At 7 weeks of age, they were divided into four
groups: (1) Zucker lean rats (ZL, n = 7); (2) untreated
ZDF rats (ZDF, n = 6); (3) ZDF rats treated with 50mg/kg
body weight aminoguanidine (AG, n = 6); (4) ZDF rats
treated with 50mg/kg body weight KIOM-79 (KIOM-79, n
= 7). KIOM-79 and AG were dissolved in water and given
orally. Rats were allowed free access to water and food for
13 weeks, including adaptation for one week. At the end of
the experimental period, rats were anesthetized with diethyl
ether and killed. After the aorta was removed, one part was
ﬂash frozen in liquid nitrogen and stored at −80◦C until
analysis and one part ﬁxed with 4% paraformaldehyde for
histological analysis.
2.3. Reverse Transcription Polymerase Chain Reaction (RT-
PCR) and Real-Time PCR. Total RNA isolation and RT-
PCR were as previously described in [13]. Total RNA was
then reverse transcribed to cDNA using the IScript cDNA
synthesis kit (Bio-Rad, USA). The following sequences were
performed for each PCR reaction. Primer sequences used for
the analyses of RAGE and β-actin mRNA were as follows:
RAGE sense, 5 -ACT ACC GAG TCC GAG TCT ACC A-
3 ; RAGE antisense, 5 -GCT CTG ACC GAA GCG TGA-
3 ; β-actin sense, 5 -TCA TTG ACC TCA ACT ACA-3 ; β-
actin antisense, 5 -CAA AGT TGT CAT GGA TGA CC-3 .
PCR products were run on a 1.2% agarose gel containing
ethidium bromide (EtBr) and quantitated with densitometry
(Las-3000, Fuji photo, Japan). Real-time quantitative PCR
analysis was carried out in a 48-well plate using the
Opticon MJ Research instrument (Bio-Rad, USA). The
following primers were used in this study: MCP-1 sense, 5 -
GAG TCG GCT GGA GAA CTA CAA GAG; MCP-1 anti-
sense, 5 -ATG TAC TTC TGG ACC CAT TCC TTA TTG-
3 ; VEGF sense-CCG TCC TGT GTG CCC CTA ATG-3 ;
VEGF antisense TCT CTC CTA TGT GCT GGC TTT GG-
3 ;V C A M - 1s e n s e ,5  -CCC AAA CAAA GGC AGA GTA-
CAC AG-3 ; VCAM-1 antisense, 5 -TTG AGCAGG TCA-
GGT TCA CAG G-3 ; GAPDH sense, 5 -CAA GTT CAA -
CGG CAC AGT CAA GG-3 ; GAPDH antisense, 5 -ACA-
TAC TCA GCA CCA GCA TCA CC-3 . Real-time PCR
was performed in identical conditions. Ampliﬁcation and
quantiﬁcation of the target gene expression were performed
with the iTaq SYBr green mix (Bio-Rad, USA) and Bio-
Rad Chromo 4/Opticon system. Relative quantiﬁcation was
performed with the relative comparative threshold (CT)
method and analyzed using the software provided by the
manufacturer.
2.4. Immunohistochemical Staining. Immunohistochemistry
was conducted on paraﬃn sections using the following
antibodies: goat polyclonal anti-MCP-1 and VCAM-1 (Santa
Cruz, USA), mouse monoclonal anti-iNOS (BD transduc-
tion Lab, USA), and mouse monoclonal anti-AGEs (6D12,
Transgenic, Japan). Paraﬃn-embedded aorta sections (4μm
thick) were deparaﬃnized, rehydrated, and treated with 3%
H2O2 for 10min. Sections were blocked with 2% animal-free
serum for 30min at 37◦C. Following 1-hour incubation with
primary antibodies, sections were incubated with an LSAB
kit (DAKO, USA) and visualized by 3,3 -diaminobenzidine
tetrahydrochloride or nitroblue tetrazolium (NBT) and 5-
bromo-4-chloro-3-indolylphosphate (BCIP). The sections
were counterstained with hematoxylin. All stained sections
were visualized on a computer display with an Olympus
DP71 camera connected to a light Olympus microscope
(Tokyo, Japan). The degree of protein expression was ana-
lyzed using Image J software (NIH) by an observer blinded
to the experimental design.
2.5. Western Blot Analysis. T h ea o r t a sf r o me a c hg r o u p
(0.1–0.2g) were lysed in solutions containing 250mM
sucrose, 1mM ethylenediaminetetraacetic acid (EDTA),
0.1mM phenylmethylsulfonyl ﬂuoride (PMSF), and 20mM
potassiumphosphatebuﬀer,atpH7.6withahomogenizerat
3000rpm. The protein was separated to PVDF membranes
(Bio-Rad, USA). Membranes were probed with anti-RAGE
andiNOS antibody (BDtransduction Lab,USA).Thebound
horseradish peroxidase-conjugated secondary antibody was
detected using an enhanced chemiluminescence detection
system (iNtRON Biotechnology, Republic of Korea). Protein
expression levels were determined by analyzing the signals
captured on the PVDF membranes using an image analyzer
(Las-3000, Fuji photo Japan).
2.6. Measuring of NF-κBA c t i v i t y .To localize the NF-κB
activity in aorta section, Southwestern histochemistry was
performed as described by Koji et al. [18]. Brieﬂy, com-
plementary oligonucleotides containing an NF-κB bindingEvidence-Based Complementary and Alternative Medicine 3
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Figure 1: The eﬀects of KIOM-79 treatment on the expression of
AGEs in the aorta of ZDF rats. This ﬁgure included representative
histological staining of the aorta. AGE staining in the aorta of
ZL rats (a), untreated ZDF rats (b), ZDF rats treated with AG
(50mg/kg) (c), and ZDF rats treated with KIOM-79 (50mg/kg)
(d). Original magniﬁcation: ×400. Quantitative analysis of the AGE
stain was calculated. All data were expressed as mean ± S.E.M. ∗P
< .01 compared with ZL rats; #P < .01 compared with untreated
ZDF rats.
consensus sequence were synthesized as follows: 5 -AGT-
TGA GGG GAC TTT CCC AGG C-3 .T h ep r o b ew a s
labeled with digoxigenin (Roche, Germany). Formalin-ﬁxed
and paraﬃn-embedded aorta tissue sections were deparaf-
ﬁnized and rehydrated. Sections were subsequently digested
with pepsin A (433U/mg) and then incubated with the
labeled probe (100pM) at 37◦C overnight. After washing,
sections were incubated with antidigoxigenin antibody con-
jugated with alkaline phosphatase (Roche, Germany) for
1h o u ra t3 7 ◦C. The color reaction was developed using
NBT/BCIP. The following were used as negative controls:
(1) absence of probe, (2) mutant NF-κB probe labeled
with digoxigenin, and (3) competition assays with a 200-
fold excess of unlabeled NF-κB followed by incubation with
labeled probe. In each case, the numbers of positive cells
in the aorta section were counted in a blinded manner.
For EMSA assay, nuclear extracts from the whole aorta
were prepared with a kit according to the manufacturer’s
instructions (Pierce Biotechnology, USA). EMSA assay was
performed by incubating 15μgo fn u c l e a rp r o t e i ne x t r a c t
with IRDye 700-labeled NF-κB oligonucleotide (LI-COR
bioscience, USA) or unlabelled probe for cold competition.
EMSA gels were analyzed and images were captured and
quantiﬁed using the LI-COR Odyssey infrared laser imaging
system (LI-COR Bioscience, USA).
2.7. Data Analysis. For multiple experiments, the results are
expressed as mean ± S.E.M. Two-tailed Student’s t-tests were
used to compare two groups using PRISM software (Graph
Pad, USA). Values of P < .05 were considered statistically
signiﬁcant.
3. Results
3.1. Accumulation of AGEs in the Aorta. We investigated
the eﬀect of KIOM-79 on AGE accumulation in the aortas
of ZDF rats using immunohistochemical staining. Using
quantitative analysis, we determined that the expression of
AGEs in untreated ZDF rat was increased compared with
age-matched ZL rats. The treatment of KIOM-79 or AG in
ZDF rats signiﬁcantly reduced the AGE expression by 37.8
and 80.4%, respectively, compared to untreated ZDF rats (P
< .01) (Figure 1).
3.2. Expression of RAGE in the Aorta. Inhibition of the
AGEs/RAGE interaction prevents the progression of the
pathogenetic pathway for diabetic complications [19]. Thus,
to determine whether KIOM-79 inhibits RAGE expression in
the aorta of diabetic rats, RAGE expression was determined
by RT-PCR and Western blot. As shown in Figures 2(a) and
2(b), RAGE mRNA and protein expression in the untreated
ZDF rats was signiﬁcantly increased compared with ZL rats,
whereas KIOM-79 or AG markedly decreased its expression
compared with untreated ZDF rats (P < .05).
3.3. Expression of Inﬂammatory Factors in the Aorta. We
examined the eﬀect of KIOM-79 on the expression of
MCP-1, VEGF, and VCAM-1, all of which are contributed
to vascular inﬂammation. We measured the expression of
MCP-1, VCAM-1, and VEGF in the aorta by immunohis-
tochemistry and found that MCP-1, VEGF, and VCAM-1
were expressed throughout the aorta of untreated ZDF rats
compared with ZL rats. ZDF rats treated with KIOM-79
or AG had signiﬁcantly reduced levels of MCP-1, VEGF,
and VCAM-1 expression compared with untreated ZDF
rats (P < .05) (Figures 3(A), 3(B), and 3(C)). However,
AG-treated ZDF rats had only a slight decrease in MCP-1
staining. Tocorroborateourimmunohistochemical ﬁndings,
we measured the mRNA expression of MCP-1, VEGF, and
VCAM-1 by real-time-PCR. As shown in Figures 3(D)–
3(F), the mRNA levels of MCP-1, VEGF, and VCAM-1 in
untreated ZDF rats were signiﬁcantly increased compared
with ZL rats. Treatment with KIOM-79 or AG markedly
decreased these inﬂammatory factors compared to untreated
ZDF rats (P < .05). ZDF rats treated with AG showed a slight
reduction of MCP-1 mRNA expression and a signiﬁcant4 Evidence-Based Complementary and Alternative Medicine
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Figure 2: The eﬀects of KIOM-79 treatment on the expression of RAGE in the aorta. The relative levels of speciﬁc mRNAs (a) and protein
(b) were assessed by RT-PCR and Western blot analysis. Results were normalized to actin. All data are expressed as mean ± S.E.M. ∗P < .01
compared with ZL rats; #P < .05 compared with untreated ZDF rats.
decrease in the mRNA level of both VEGF and VCAM-1 (P
< .05).
3.4. Activation of NF-κB and Expression of iNOS in the Aorta.
We then investigated whether KIOM-79 inhibits the NF-κB
activity by using Southwestern histochemistry. This method
allowed the localization of the activated nuclear factor in
aorta. Untreated ZDF rats had markedly increased NF-κB
positive staining in the aorta section (both endothelial layer
and smooth muscles lesion) compared to ZL rats (approxi-
mately 290.2% of ZL rats) (Figure 4(A)a–d). Treatment with
KIOM-79 or AG signiﬁcantly decreased NF-κB staining in
the aorta by 42.2 or 22.8% compared to untreated ZDF
rats. We also conﬁrmed that nuclear extracts from the whole
aortic tissues were subjected to analysis for NF-κBD N A -
binding activity as measured by EMSA. The results showed
that NF-κB DNA-binding activity was signiﬁcantly reduced
in treated with KIOM-79 or AG in ZDF rats (Figure 4(C)).
Quantitative analysis showed an increased number of NF-
κB positive staining and NF-κB activity in aorta section of
ZDF rats compared with ZL rats. KIOM-79 or AG treatment
signiﬁcantly reduced the NF-κB staining and activity in the
ZDF rats (P < .05).
We examined the expression of iNOS in the aorta by
immuohistochemistry and Western blot analysis. There was
a striking diﬀerence between the amount of iNOS present in
the ZL rats and that in untreated ZDF rats (approximately
162% of ZL rats) (Figure 4(B)e–h). iNOS staining was
signiﬁcantly decreased in ZDF rats treated with either AG
or KIOM-79 by 38.9 or 43.7%, respectively, compared to
untreated ZDF rats (P < .05). The expression of iNOS was
markedly increased in the untreated ZDF rats (Figure 4(D)).
However, the treatment of KIOM-79 or AG signiﬁcantly
decreased the expression of iNOS.
4. Discussion
Several studies have demonstrated that vascular inﬂam-
matory processes play a crucial role in the development
of diabetic macrovascular dysfunction [20]. In the present
study, in order to verify the preventive eﬀects of KIOM-79
in diabetic macrovascular disease, we investigated whether
the administration of KIOM-79 inhibited the expression of
proinﬂammatory cytokines and chemokines in the vascular
tissue of Zucker diabetic fatty (ZDF) rats. In our previous
study, the treatment of KIOM-79 in STZ-induced diabetic
rats (250 and 500mg/kg body weight) has dose-dependently
prevented the development of diabetic nephropathy [14].
KIOM-79 (500mg/kg body weight) retarded the develop-
ment of diabetic nephropathy in Goto-Kakizaki rats [15].
Diabeticdb/dbmicetreatedwithKIOM-79(150mg/kgbody
weight) show reduced apoptotic cell death and accumulation
of AGEs in the retina [21]. Recently, it was reported that the
long-term treatment of KIOM-79 (50mg/kg body weight)
in ZDF rat prevented the progress of diabetic nephropathy
[22]. Based on our previous studies, we assumed that the
minimum eﬀective dose of KIOM-79 is 50mg/kg body
weight in animal models. Thus, in this study, we investigated
the eﬀect of KIOM-79 (50mg/kg body weight) on diabetic
vascular inﬂammation in ZDF rat, which is a murine modelEvidence-Based Complementary and Alternative Medicine 5
(a) (b)
(c) (d)
0
1
2
3
4
5
M
C
P
-
1
p
o
s
i
t
i
v
e
a
r
e
a
s
(
%
)
ZL ZDF AG KIOM-79
∗
#
(A)
(e) (f)
(g) (h)
0
5
10
15
20
V
E
G
F
p
o
s
i
t
i
v
e
a
r
e
a
s
(
%
)
ZL ZDF AG KIOM-79
∗
#
#
(B)
(a) (b)
(c) (d)
0
5
10
15
20
V
C
A
M
-
1
p
o
s
i
t
i
v
e
a
r
e
a
s
(
%
)
ZL ZDF AG KIOM-79
∗
# #
(C)
0
1
2
3
4
M
C
P
-
1
m
R
N
A
e
x
p
r
e
s
s
i
o
n
(
M
C
P
-
1
/
G
A
P
D
H
)
ZL ZDF AG KIOM-79
∗
#
(D)
0
1
2
3
4
V
E
G
F
m
R
N
A
e
x
p
r
e
s
s
i
o
n
(
V
E
G
F
/
G
A
P
D
H
)
ZL ZDF AG KIOM-79
∗
#
#
(E)
0
1
2
3
4
5
V
C
A
M
-
1
m
R
N
A
e
x
p
r
e
s
s
i
o
n
(
V
C
A
M
-
1
/
G
A
P
D
H
)
ZL ZDF AG KIOM-79
∗
# #
(F)
Figure 3: The eﬀects of KIOM-79 treatment on expression of MCP-1, VEGF, and VCAM-1 in the aorta. Representative immunohistochem-
istry images for MCP-1 (A), VEGF-1 (B), and VCAM-1 (C) staining in the aorta of Zucker lean rats ((a), (e), and (i)), untreated ZDF rats
((b),(f),and(j)),ZDFratstreatedwithAG(50mg/kg)((c),(g),and(k)),andZDFratstreatedwithKIOM-79(50mg/kg)((d),(h),and(l)).
Original magniﬁcation: ×400. After real time-PCR analysis, MCP-1 (D), VEGF (E), and VCAM-1 (F) levels were normalized to GAPDH. All
data are expressed as mean ± S.E.M. ∗P < .01 compared with ZL rats; #P < .05 compared with untreated ZDF rats.
for type 2 diabetes. ZDF rats show the vascular dysfunction
seen in the coronary and mesenteric arteries and preceding
the changes in conduit (aorta) arteries [23]. In this study,
we found that KIOM-79 inhibited the accumulation of
AGEs and RAGE expression in the aorta of ZDF rats.
Furthermore, KIOM-79 treatment suppressed the diabetic
vascular inﬂammatory process through NF-κB activation,
leading to decreased MCP-1, VEGF, VCAM-1, and iNOS.
AGEs, sugar-derived irreversible protein modiﬁcations,
have been implicated in the pathogenesis of diabetic vas-
cular complications [2, 3]. AGEs exert their cellular eﬀects
mainly through interaction with cell-surface receptors, that
is, RAGE [6]. The interaction of AGEs and RAGE leads
to the activation of the inﬂammatory response, including
the production of cytokines and chemokines. Thus, the
inhibition of AGE formation, blockade of the AGE-RAGE
interaction, and suppression of RAGE expression or its
downstream pathways suggest novel therapeutic strategies
for the treatment of the vascular complications of diabetes
[6, 7]. AGE inhibitors, such as AG, pyridoxamine, and ALT-
711 (alagebrium),have been reported to attenuate numerous
functional and structural manifestations of diabetic vascular
diseaseinexperimentalanimals[5,24].AGalsoinhibitedthe
gene expression of the renal and vascular RAGE in a diabetic
animal model [25]. Our previous studies have shown that
KIOM-79 inhibits the formation of AGEs more in vitro than
AG and also reduces AGE accumulation in the kidney and
retina of type 1 and 2 diabetic animal models. Furthermore,
in vitro KIOM-79 inhibited collagen-AGE cross-linking
better than AG [22]. As our study demonstrated, KIOM-79
also reduced AGE accumulation and RAGE expression in the
aorta of ZDF rats (Figures 1 and 2). Our results suggested
that KIOM-79 inhibits the accumulation of AGEs in the
vascular tissue of ZDF rats.
NF-κB is a multiprotein complex that can activate
various genes involved in multiple cellular functions. In
unstimulated cells, NF-κB resides in the cytoplasm in an
inactivecomplexwithaninhibitor,kappaB(IκB).Pathogenic
stimuli causes the release of IκB and allows NF-κBt oe n t e r
the nucleus, bind to DNA recognition sites in regulatory
regions of the target gene, and inﬂuence the transcription
of speciﬁc genes [26, 27]. Recently, AGEs have been shown6 Evidence-Based Complementary and Alternative Medicine
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Figure 4:Theeﬀects of KIOM-79treatment on activation of NF-κB and iNOS in theaorta. Representative NF-κB(A)andiNOS (B)staining
in the aorta in Zucker lean rats ((a), (e)), untreated ZDF rats ((b), (f)), ZDF rats treated with AG (50mg/kg) ((c), (g)), and ZDF rats treated
with KIOM-79 (50mg/kg) ((d), (h)). NF-κB staining was observed in the nuclei of both the endothelial layer and smooth muscle lesion
(arrow), and iNOS staining (brown color) was observed in the aorta. Hematoxylin counterstain. Original magniﬁcation: ×400. Analysis of
EMSA of NF-κB activation (C) and Western blot of iNOS (D). Quantitative analyses of the NF-κB and iNOS stains were completed. All data
were expressed as mean ± S.E.M. ∗P < .01 compared with ZL rats; #P < .05 compared with untreated ZDF rats.
to stimulate the activation of NF-κB through binding to
RAGE [28]. In the development of the cardiovascular com-
plications of diabetes, AGE-RAGE interaction upregulates
thetranscription factorNF-κB and its target genes,including
the adhesion molecules (VCAM-1 and MCP-1) [4, 29].
InﬂammatoryfactorssuchasMCP -1andV CAM-1accelerate
atherosclerosisindiabeticpatients[30,31].AstudybyRenier
et al. [32] demonstrated that AGEs induced the expression
of MCP-1 in endothelial cells and MCP-1 secretion by
intima cells attracted monocytes to VCAM-1 on the vessel,
leading to an increased inﬂammatory response. Angiogenic
factors, such as VEGF, are also involved in the pathology of
chronic inﬂammatory disease [33]. AGEs have been shown
to induce VEGF expression in retinal endothelial cells, and a
direct stimulatory eﬀect of AGEs on retina vascular VEGF
expression has been documented [34]. Moreover, NF-κB
controls the expression of VEGF both directly [35]a n d
indirectly through the induction of expression of AP-1 [36].
Several studies have demonstrated that in vascular smooth
muscle cells, NF-κB binds to the iNOS promoter, increasing
iNOS expression [37], and iNOS upregulation has been
found in microvessels of experimental diabetic rodents [38].Evidence-Based Complementary and Alternative Medicine 7
Expression of iNOS in the vessel may contribute to altered
vascular function during inﬂammation and cardiovascular
diseases [39]. Our present study demonstrated that ZDF rats
had more activated NF-κB and iNOS, as well as increased
MCP-1, VEGF, and VCAM-1 expression, compared to ZL
rats, and treatment with KIOM-79 or AG reversed this eﬀect
(Figures 3 and 4). AG, the positive control drug, signiﬁcantly
reduced iNOS expression in ZDF rats, as the iNOS-selective
inhibitors [37] VCAM-1 gene expression was decreased by
AG treatment, consistent with previous ﬁndings that AG
lowered AGE levels by inhibiting VCAM-1 expression in
human vascular endothelial cells exposed to glycated protein
[40]. KIOM-79 prevented the upregulation of iNOS and
activation of NF-κB in the aorta of diabetic rats, consistent
with the recent report that KIOM-79 has exhibited anti-
inﬂammatory eﬀects by blocking NF-κBa c t i v a t i o ni nL P S -
induced iNOS gene expression in macrophages [16]. These
data suggest that KIOM-79 can protect diabetic vascular
inﬂammation by inhibiting NF-κB activation, which in turn
decreases iNOS, VEGF, MCP-1, and VCAM-1 expressions.
Taken together, we concluded that KIOM-79 inhibits
AGE accumulation and reduces RAGE expression in the
diabetic aorta. Decreased AGE/RAGE interaction decreases
NF-κB activation, subsequently decreasing the expression
of multiple inﬂammatory factors, including MCP-1, VEGF,
VCAM-1, and iNOS. The present study shows that KIOM-
79 may help in the prevention and delay of diabetes-induced
vascular inﬂammation.
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